#1 Clinical Trials Search in Europe

Ecoo1A

Clinical trials are underway to evaluate the effectiveness of ExPEC9V, a new vaccine designed to prevent invasive extraintestinal pathogenic Escherichia coli (ExPEC) disease in older adults. These studies focus on adults aged 60 and above, particularly those with a history of urinary tract infections, as they are at higher risk for invasive E. coli infections. The trials aim to assess the vaccine’s ability to stimulate immune responses and protect against various forms of E. coli-related illnesses, including urinary tract infections and more severe invasive diseases.

Table of Contents

What is ECOO1A?

ECOO1A is one of the key components of a new vaccine called ExPEC9V (also known as JNJ-78901563). This vaccine is currently being developed to prevent invasive diseases caused by certain types of Escherichia coli (E. coli) bacteria[1]. ECOO1A is part of a group of substances that make up this vaccine, which is designed to protect against multiple strains of E. coli.

What Disease Does ECOO1A Target?

The ExPEC9V vaccine, which includes ECOO1A, is aimed at preventing Invasive Extraintestinal Pathogenic Escherichia coli Disease (IED). This is a serious condition caused by certain E. coli bacteria that can spread beyond the urinary tract and cause infections in other parts of the body[2]. These infections can be severe and may include:

  • Urosepsis: A life-threatening condition where an infection that starts in the urinary tract spreads to the bloodstream
  • Bacteremia: The presence of bacteria in the blood
  • Pyelonephritis: A kidney infection
  • Urinary Tract Infections (UTIs): Infections of the urinary system, which can sometimes lead to more serious conditions if left untreated

Vaccine Composition

The ExPEC9V vaccine, which includes ECOO1A, is composed of several components targeting different strains of E. coli. These components are[1]:

  • ECOO1A
  • ECOO2
  • ECOO4
  • ECOO6A
  • ECOO15
  • ECOO16
  • ECOO18A
  • ECOO25B
  • ECOO75

Each of these components targets a specific O-serotype of E. coli. O-serotypes are different variations of the bacteria that can cause disease. By including multiple components, the vaccine aims to provide broad protection against several dangerous strains of E. coli.

Clinical Trials

The ExPEC9V vaccine, which includes ECOO1A, is currently undergoing Phase 3 clinical trials. These are large-scale studies designed to test the safety and effectiveness of the vaccine in humans. Two major trials are currently in progress[1][2]:

  1. A study evaluating the vaccine in adults aged 65 years or older, alongside a high-dose influenza vaccine. This trial aims to assess how well the ExPEC9V vaccine works when given at the same time as a flu shot.

  2. A study focused on adults aged 60 years and older who have a history of urinary tract infections in the past two years. This trial is specifically looking at how well the vaccine prevents invasive E. coli disease in this high-risk group.

Potential Benefits

If successful, the ExPEC9V vaccine containing ECOO1A could provide several benefits[2]:

  • Prevention of invasive E. coli infections, which can be life-threatening, especially in older adults
  • Reduction in the number of urinary tract infections caused by the targeted E. coli strains
  • Decreased need for hospitalization due to E. coli infections
  • Potential improvement in quality of life for those at high risk of these infections
  • Possible reduction in the use of antibiotics, which could help combat antibiotic resistance

Safety and Side Effects

As the vaccine is still in clinical trials, comprehensive safety data is not yet available. However, the trials are closely monitoring for any side effects[1][2]. Common side effects of vaccines can include:

  • Pain, redness, or swelling at the injection site
  • Mild fever
  • Fatigue
  • Headache
  • Muscle aches

The clinical trials are designed to carefully assess both the short-term and long-term safety of the vaccine.

Who Can Receive the Vaccine?

The current clinical trials are focusing on specific groups[1][2]:

  • Adults aged 65 years or older
  • Adults aged 60 years or older with a history of urinary tract infections

These groups are being studied because they are at higher risk for invasive E. coli infections. If the vaccine proves successful, it may eventually be recommended for these high-risk groups. However, the exact recommendations will depend on the results of the clinical trials and subsequent approval by regulatory authorities.

Conclusion

ECOO1A, as part of the ExPEC9V vaccine, represents a promising advancement in the prevention of invasive E. coli diseases. While still in the testing phase, this vaccine has the potential to significantly reduce the burden of these serious infections, particularly in older adults and those with a history of urinary tract infections. As clinical trials progress, more information will become available about the vaccine’s effectiveness and safety profile.

Aspect Details
Vaccine Name ExPEC9V (JNJ-78901563)
Target Population Adults aged 60 years and older with a history of urinary tract infections
Primary Objectives Prevent invasive E. coli disease (IED) caused by specific ExPEC serotypes
Secondary Objectives Prevent UTIs, pyelonephritis, and hospitalized IED events; evaluate immunogenicity and safety
Administration Intramuscular injection, single dose of 88 μg
Study Design Randomized, double-blind, placebo-controlled Phase 3 trials
Key Endpoints Incidence of IED events, antibody responses, safety assessments
Potential Benefits Reduction in E. coli-related infections, hospitalizations, and improved quality of life for older adults

FAQ

  • What is ExPEC9V? ExPEC9V is a vaccine being developed to prevent invasive extraintestinal pathogenic Escherichia coli (ExPEC) disease. It targets nine specific E. coli serotypes (O1, O2, O4, O6, O15, O16, O18, O25, and O75) that are common causes of infections outside the intestinal tract.
  • Who is the target population for the ExPEC9V vaccine trials? The trials are focusing on adults aged 60 years and older, particularly those with a history of urinary tract infections in the past two years. This group is considered at higher risk for invasive E. coli infections.
  • What are the main objectives of the ExPEC9V clinical trials? The main objectives are to evaluate the vaccine's efficacy in preventing invasive E. coli disease, assess its safety and immune response in older adults, and determine its effectiveness against various E. coli-related conditions such as urinary tract infections and bloodstream infections.
  • How is the vaccine administered? ExPEC9V is administered as an intramuscular injection. In the trials, participants receive either the vaccine or a placebo, with some studies also evaluating its co-administration with influenza vaccines.
  • What are the potential benefits of the ExPEC9V vaccine? If successful, the ExPEC9V vaccine could help prevent invasive E. coli diseases, reduce hospitalizations due to these infections, and improve the quality of life for older adults who are at risk of recurrent urinary tract infections and more severe E. coli-related illnesses.

Ongoing Clinical Trials on Ecoo1A

  • Study on the Safety and Immune Response of JNJ-78901563 and High-dose Influenza Vaccine in Preventing E. coli Infections in Adults Aged 65 and Older

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Poland

  • Study of ExPEC9V vaccine for preventing invasive E.

    Not recruiting

    3 1
    Investigated diseases:
    Investigated drugs:
    Czechia Denmark France Germany The Netherlands Spain +1

Glossary

  • ExPEC9V: A vaccine being developed to prevent invasive extraintestinal pathogenic Escherichia coli (ExPEC) disease, targeting nine specific E. coli serotypes.
  • Extraintestinal pathogenic Escherichia coli (ExPEC): Strains of E. coli bacteria that can cause infections outside the intestinal tract, such as urinary tract infections, bloodstream infections, and other invasive diseases.
  • Invasive E. coli Disease (IED): A serious infection caused by E. coli bacteria that spreads beyond the initial site of infection, such as the urinary tract, into the bloodstream or other normally sterile body sites.
  • Urinary Tract Infection (UTI): An infection affecting any part of the urinary system, including the kidneys, bladder, ureters, and urethra, often caused by bacteria such as E. coli.
  • Pyelonephritis: A type of urinary tract infection that affects one or both kidneys, typically causing more severe symptoms than a simple bladder infection.
  • Bacteremia: The presence of bacteria in the bloodstream, which can lead to serious systemic infections.
  • Sepsis: A life-threatening condition that occurs when the body's response to infection causes widespread inflammation and organ dysfunction.
  • Immunogenicity: The ability of a substance, such as a vaccine, to provoke an immune response in the body.
  • Antibody titers: A measurement of the amount or concentration of antibodies in the blood, used to assess immune response to vaccines or infections.
  • Placebo: An inactive substance or treatment used in clinical trials as a control to compare against the effects of the investigational drug or vaccine.

References

  1. http://clinicaltrials.eu/trial-id/2023-504168-40-00
  2. http://clinicaltrials.eu/trial/study-on-jnj-78901563-vaccine-for-preventing-invasive-e-coli-disease-in-adults-60-with-recent-urinary-tract-infections/